Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Core Viewpoint - Intensity Therapeutics, Inc. successfully raised $6.6 million in gross proceeds through an At-the-Market (ATM) offering, enhancing its financial position to support ongoing clinical trials into the second half of 2026 [1][2]. Financial Summary - The company sold 19,868,658 shares at an average price of $0.3323 per share, resulting in $6.3 million net proceeds after costs [1]. - The average sales price per share was over 10% higher than the price from a public offering completed in June 2025 [2][6]. Company Overview - Intensity Therapeutics is a late-stage clinical biotechnology company focused on developing intratumoral cancer therapies using proprietary non-covalent conjugation technology [1][5]. - The lead product candidate, INT230-6, is designed for direct intratumoral injection and combines two potent anti-cancer agents, cisplatin and vinblastine sulfate, with a diffusion enhancer [4][5]. - INT230-6 aims to kill tumors while engaging the immune system without causing immunosuppression, representing a novel approach to cancer treatment [4][5]. Clinical Development - The company has completed two clinical studies with over 200 patients enrolled, including a Phase 1/2 study in metastatic cancers and a Phase 2 randomized control trial in locally advanced breast cancer [5]. - A Phase 3 trial in soft tissue sarcoma and a Phase 2 study in collaboration with the Swiss Cancer Group are currently underway [5].